I n December 2016, the 21st Century Cures Act was signed into law in the United States. 1 It contained a provision intended to promote real-world data studies of medication use and outcomes in routine clinical settings in US Food and Drug Administration (FDA) authorization of additional indications for already approved prescription drugs.
1 Such data, with or without randomization, are drawn from health care use data, insurance claims, registry studies, and/or electronic health record systems in typical clinical settings of care. [2] [3] [4] Although the FDA has long used such data to clarify the safety of medications, the data can seldom establish a drug's effectiveness. Well-designed randomized clinical trials are the criterion standard for assessing whether a drug is efficacious because random treatment assignment and a controlled research environment can more readily support causal inferences. In recent years, new methodologic approaches have improved the validity and reproducibility of nonrandomized data, including new-user designs, 5 active comparators, propensity score (PS) matching, and controlling for disease risk scores. 6, 7 Other important aspects include assessing covariates before cohort entry (to avoid adjusting for intermediate variables) and defining cohort entry as the time when the patient first receives the exposure of interest (to decrease the possibility of immortal time bias). [6] [7] [8] Can such analytic techniques confirm supplemental indications for already approved drugs? Approximately half of all drugs approved in the United States are later approved for supplemental indications, modifications to the initial indication, or expanded populations.
9,10 Supplemental indications are typically identified on the basis of prospective clinical trials.
To determine whether real-world data analyses can confirm a supplemental indication, we identified a supplemental approval amenable to study and applied the same inclusion and exclusion criteria and outcomes measurements that were used in the pivotal randomized clinical trial.
Methods
Our cohort study was conducted in commercially insured patients using the MarketScan health care database provided by Truven (January 1, 2003 1, , through September 30, 2009 ). This nationwide database captures anonymized longitudinal, individual-level data on health care use, patient demographics, inpatient and outpatient diagnostic and procedural codes, and pharmacy dispensing of prescription drugs for more than 60 million commercially insured people in the United States. The study was approved by the institutional review board at Brigham and Women's Hospital, including a waiver for informed consent, and a valid data licensing agreement was in place. All data were anonymized and deidentified.
Data Sources
To identify an experimental setting, we reviewed all supplemental applications to the FDA from 2005 to 2014 and their accompanying clinical trials. 9 The supplemental indications were classified into 3 mutually exclusive categories: new indication (n = 138), modification (n = 86), and expansion (n = 66) (eAppendix in the Supplement). 9 Of the 138 new indications, 108 (78.3%) of the pivotal clinical trials had a primary outcome that was not identifiable in US longitudinal health care databases (eg, pathology results, change in clinical scores, and radiologic tumor response), 12 (8.7%) did not have an active comparator, 4 (2.9%) were based on in-hospital medication administration (eg, postoperative nausea medication, anesthetic medications), and 14 (10.1%) were potentially replicable with the claims data available to us. Of the 14, we selected telmisartan a priori and did not analyze data for the other 13 (eAppendix in the Supplement). The angiotensin receptor blocker (ARB) telmisartan (Micardis) was approved as an antihypertensive in 1998. In October 2009, it was approved supplementarily for cardiovascular risk reduction in patients 55 years or older who are unable to take angiotensin-converting enzyme inhibitors (ACE-Is) and have a high risk of major cardiovascular events. Telmisartan was an optimal case study for 3 reasons. First, the primary outcome in the pivotal supplemental indication trial could be accurately identified in health care use data. Second, the randomized clinical trial used an active comparator, the ACE-I ramipril (Altace), which would minimize confounding in cohort studies. 3, 7 Third, the inclusion criteria, exclusion criteria, and baseline patient characteristics were identifiable in claims data. The trial that identified the supplemental indication for telmisartan for cardiovascular risk reduction, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), was published in April 2008.
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ONTARGET's primary objectives were to determine whether telmisartan was at least as effective as ramipril at reducing cardiovascular risk and to assess whether the combination of telmisartan and ramipril was more effective than ramipril alone. The trial was conducted across 733 centers in 40 countries between 2001 and 2008. 11 
Study Cohort
Potentially eligible patients must have had at least 6 months of continuous enrollment in a participating health plan before the date of cohort entry. Our inclusion and exclusion cri-
Key Points
Question Can health care databases be used to confirm a supplemental indication that has been demonstrated in a randomized clinical trial for an approved medication?
Findings This cohort study replicated the results of a randomized clinical trial that established the supplemental indication for telmisartan by using data from a US health care database (insurance claims data) available at the time that the supplemental indication was approved. Similar to the randomized clinical trial, our study revealed a decreased risk of angioedema with telmisartan compared with ramipril.
Meaning
In certain clinical scenarios, database studies may support supplemental effectiveness applications for already approved medications.
teria mirrored those of ONTARGET. 11 We included patients 55 years or older who filled a new prescription for telmisartan or ramipril (no fills for either drug or any other ACE-I or ARB during the prior 180 days). Cohort entry date was the first day of a prescription fill. As in ONTARGET, we included patients with a diagnosis of coronary artery disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus during the 180 days before cohort entry. As in ONTARGET, we excluded patients with a limited life expectancy (ie, living in a hospice, palliative care facility, or a nursing home and those with cancer), liver disease, syncope or a recent myocardial infarction (within 2 days of cohort entry), transient ischemic attack (within 7 days of cohort entry), percutaneous transluminal coronary angiography (within 30 days of cohort entry), or hospitalization for congestive heart failure during the 180 days before cohort entry. Other exclusion criteria used in ONTARGET were not applied because they were not readily identifiable (known allergy to study medication, unable to tolerate study medication, hemodynamically significant primary valvular or outflow tract obstruction, uncorrected volume or sodium depletion, planned cardiac procedure, blood pressure >160/100 mm Hg despite treatment, significant renal artery stenosis, and angina in the absence of multivessel coronary artery disease) or rare (hereditary fructose intolerance, complex congenital heart disease, primary hyperaldosteronism, and heart transplant). We also excluded patients who previously received any ACE-I or ARB.
Study End Point
Our primary outcome was a composite of myocardial infarction, stroke, or hospitalization for congestive heart failure using the primary discharge diagnosis code for an inpatient visit (see eTable 1 in the Supplement for International Classification of Diseases, Ninth Revision codes). These definitions have satisfactory measurement characteristics; the positive predictive value for myocardial infarction was 93% or higher; stroke, 81% or higher; and congestive heart failure, 87%orhigher .
12-14 Cardiovascular deaths were included in the composite outcome if they occurred during a hospitalization for myocardial infarction, stroke, or heart failure but not outside the hospital.
Statistical Analysis
Our primary analysis compared the rates of the composite end point among patients initiating treatment with telmisartan vs ramipril. Data were censored for patients when they discontinued use of their initial medication, switched to the comparator medication, experienced a study outcome, disenrolled from their health plan, or died, or on September 30, 2009. 15 To address confounding, we adjusted for 74 patient characteristics, including demographics, comorbid conditions, concurrent medications, and health care use measures, using PS methods ( To assess the robustness of our results, we also sought to confirm the well-established increased risk of angioedema for ramipril, expecting that rates of angioedema would be lower for telmisartan, as also demonstrated in ONTARGET. To further assess robustness, we replicated all study end points using a larger cohort derived from less stringent exclusion criteria by creating a cohort that allowed for past ACE-I or ARB use other than telmisartan or ramipril in the preceding 180 days. All analyses were conducted using the Aetion platform and R, version 3. In ONTARGET, the relative risk of the composite outcome of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for congestive heart failure was 1.01 (95% CI, 0.94-1.09), indicating no significant difference between telmisartan and ramipril. In our study, the PSmatched relative risk of the composite of myocardial infarc-tion, stroke, or hospitalization for congestive heart failure was almost identical (HR, 0.99; 95% CI, 0.85-1.14) ( Table 2 ).
Sensitivity Analysis
A sensitivity analysis using the last exposure to the first-used medication for 365 days without considering treatment discontinuation found that the primary end point occurred in 402 ramipril users (86 events per 1000 patients) and 363 telmisartan users (78 events per 1000 patients). This resulted in no significant difference in risk after PS matching (HR, 0.90; 95% CI, 0.77-1.04).
Validation Against a Known Causal Association
Among PS-matched individuals, there were 18 angioedema events in new users of ramipril (3.1 events per 1000 personyears) and 2 events in new users of telmisartan (0.4 events per 1000 person-years). A decreased risk (HR, 0.13; 95% CI, 0.03-0.56) of angioedema with telmisartan was also observed in ONTARGET (HR, 0.40; P = .01).
Robustness of Findings
In the cohort with less stringent exclusion criteria to allow for past ACE-I or ARB use apart from ramipril or telmisartan, we identified 8656 PS-matched new users of telmisartan and 8656 PS-matched new users of ramipril. In this cohort, there was a similar PS-matched relative risk of the composite of myocardial infarction, stroke, or hospitalization for congestive heart failure (HR, 0.97; 95% CI, 0.88-1.08) ( Table 3) . A decreased PSmatched risk of angioedema with telmisartan compared with ramipril (HR, 0.35; 95% CI, 0.17-0.71) was also revealed.
Discussion
Among patients newly prescribed telmisartan and ramipril before the FDA's decision to approve a supplemental indication for telmisartan, we found results that were almost identical to those of the randomized clinical trial that led to telmisartan's supplemental indication. We further identified and quantified the known causal association between ramipril and angioedema. This finding suggests that our data and analysis plan were sufficiently valid to detect known causal associations first identified in a prospective trial.
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This study is one of the largest to analyze real-world data to mirror a large randomized clinical trial that had established the clinical basis for a supplemental indication for a medication. In contrast to ONTARGET, which took approximately 7 years to complete and cost tens of millions of dollars, our study took approximately 12 weeks to implement for less than a hundredth of the cost. The fact that our case study bolstered the conclusions of a trial designed to identify a supplemental indication for a marketed medication and was done relatively efficiently using available data sets, rigorous epidemiologic methods, and modern software platforms supports the concept of conducting similar database analyses as part of routine practice for manufacturers submitting applications for supplemental indications to the FDA.
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Results concordant with the pivotal clinical trial can provide regulators with greater confidence in approving the indication, whereas discordant results could warrant deeper reexamination of the clinical trial or nonrandomized data. When results are discordant with the pivotal trial, an in-depth analysis of the trial and the nonrandomized study will be necessary to identify reasons for this discordance. These reasons can include issues related to study design, statistical analysis, and patient population. Additional research will be necessary to help navigate this scenario. 22 Eventually, the FDA can develop empirically based guidance on when database analyses are useful in this context and when they are less reliable as a confirmatory source.
Validity of Nonrandomized Real-world Data Analyses
There have been examples of real-world data providing results before the randomized clinical trial was completed [23] [24] [25] and nonrandomized real-world studies that changed prescribing practices for which there will likely never be randomized clinical trial findings. [26] [27] [28] [29] A common signal of quality among these studies and our current study was the use of a new-user, activecomparator design. This approach compares 2 groups of patients who newly start taking a medication and avoids comparing 2 groups with intrinsically discrepant risk profiles as would be found using a nonuser comparator or comparing new users with ongoing users. The new-user design with an active comparator allows a more homogeneous baseline population and was one of the main reasons why the observed baseline characteristics for our patients were similar even before matching. Studies such as ours require that inclusion and exclusion criteria and end points be adequately defined in a randomized clinical trial report and subsequently identifiable in the health care data set being studied. Many trials include study Pharmacoepidemiology analysis of data from nonrandomized, real-world health care databases can be used to support supplemental indications established in prospective randomized clinical trials of marketed medications. This is powerful because they represent outcomes in settings of typical care, rather than the highly controlled research environments of RCTs, and can be accomplished quickly and inexpensively. The analyses can also include subgroups of patients who are underrepresented in clinical trials, including elderly individuals, patients with many comorbidities, pregnant women, and other at-risk groups. In our study, for example, 50% of patients were women compared with approximately 26% in ONTARGET. Finally, such studies can evaluate a larger population of patients and can assess end points that trials are often underpowered to detect, such as rare adverse events.
Limitations
Our observed null finding might reflect limitations within our data set (eg, lack of out-of-hospital death data), duration of follow-up, or study design rather than a true observation. It is well established that noninferiority can appear to be present because of inadequate rigor or scale in any study, whether a randomized clinical trial or an observational analysis. 39,40 However, this does not explain the increased risk of angioedema that we observed with ramipril but not telmisartan. Some authors 41, 42 have questioned the value of PS matching over traditional risk-adjusted regression analysis, neither of which guarantee full account for unmeasured confounding. However, our unadjusted primary, secondary, and sensitivity analyses did not change meaningfully after PS matching. Another limitation of our study was an inability to assess medication adherence beyond prescription filling, although this is generally seen as a valid measure of actual use.
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Conclusions
The FDA is currently considering how it will use nonrandomized, real-world data as part of supplemental indication applications. 42, 43 In the absence of large-scale empirical comparative analyses that identify the reasons for failure and success to replicate randomized controlled findings with realworld data analyses, we performed a case study that highlights some important considerations. Many context-specific questions about study design, confounding control, data quality, and outcome validity will need to be considered. 4, 6 Preregistering study designs and analysis plans and providing a publicly available summary of the results when available, similar to the current practice of randomized clinical trials, promotes ethical conduct of these studies. Even well-designed analyses sometimes result in incorrect conclusions, and some randomized clinical trials may be inaccurate. 44 Retrospective reviews of the literature 34,45-48 provide single summarizations of the differences between these 2 approaches but provide few insights on the validity of individual real-world data analyses. To establish a meaningful baseline, the FDA will need many sets of randomized clinical trials with prospectively designed, nonrandomized analyses to match the populations included in randomized clinical trials across a range of clinical questions, each investigated with a set of designs and methods following rigorous epidemiologic principles. Regulators have a difficult task in providing specific rules for decision making in this maturing yet still developing and highly context-specific field. However, if done selectively and with principled methods, it might be feasible to use nonrandomized, real-world data to provide supportive evidence in establishing supplemental drug indications. that telmisartan was equally effective to ramipril, with fewer incidences of angioedema. Participants who received both drugs experienced more adverse events but no increase in benefits.
ONTARGET was a good choice for this demonstration: telmisartan, with a toxicity and adverse effect profile similar to ramipril, was already approved for treating hypertension, and many angiotensin receptor antagonists are noninferior to angiotensin-converting enzyme inhibitors for preventing cardiovascular events. The study by Fralick et al 1 is valuable and technically excellent; however, it examines only 1 drugindication pair of many. Thus, it is open to the criticism that generalizing from 1 positive finding to a vast field of potential treatment comparisons with observational data is analogous to painting the target around the arrow, especially considering the high probability that the telmisartan-ramipril comparison would work.
Theory and experience have shown randomization to be the key element of high-quality evidence when drawing causal inferences about therapeutic effects and when making the case for regulatory approval. The classic construct invokes a hierarchy of evidence in which randomized clinical trials (RCTs) occupy the apex of the evidence pyramid, with observational analyses relegated to lower levels. An accompanying body of folklore known as good clinical practice has accumulated around organizational and operational aspects of RCTs. Such trials, however, cannot answer every clinical question, and bureaucracy engendered by common interpretations of good clinical practice has driven the costs of traditional regulatory RCTs to such levels that many important questions are effectively unanswerable within the existing clinical research ecosystem. For example, many regulated RCTs expend substantial resources auditing data that may not be essential to the result of the trial at a cost that far exceeds the value in obtaining a reliable answer to the primary questions posed by the trial. 3 The shortcomings of traditional regulatory RCTs have long been debated. 4 During the past few decades, however, alternative approaches for understanding the effects of specific therapies have evolved. Recently, Frieden 5 pointed out that as analytical methods continue to improve, confidence in the value of observational analyses should correspondingly increase. The evidentiary standard for initial marketing approval for drugs, biologics, or medical devices is a high bar generally construed as 2 traditional RCTs demonstrating benefit in terms of 1, 649.10, 649.11, 649.12, 649.13, 649.14, 649.2, 649.20, 649.21, 649.22, 649.23, 649.24, V85.3, V85.30, V85.31, V85.32, V85.33, V85.34, V85.35, V85.36, V85.37, V85.38, V85.39, V85.4, V85.41, V85.42, V85.43, V85.44, V85.45, 539, 539.0, 539.01, 539.09, 539.8, 539.81, 539 428.xx, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 411.81, 412 429.7 2, 33510, 33511, 33512, 33513, 33514, 33516, 33517, 33518, 33519, 33520, 33521, 33522, 33523, 33530, 33534, 33534, 33536, 33545, 33572 36.01, 36.02, 36.03, 36.05, 36.09 92920, 92921, 92924, 92925, 92937, 92938, 92941, 92943, 92944, 92973, 92982, 92984, 92995, 92996 00.66 V45.82 Peripheral vascular disease 440.20 -440.24, 440.29 -440.32, 440.3, 443.9 Atrial fibrillation 427.3x Ischemic stroke 433.x1, 434.x1, 434.9, 436 403.xx, 404.xx, 572.4x, 791.2x, 791.3x, 274.10, 440.1x, 442.1x, 453.3x, 593.xx, 753.0x, 753.3x, 866.00, 866.01, 866.1x, Sepsis/Septicemia 995.91, 995.92, 038.xx Osteoarthritis 715.xx Depression 293.83, 296.2x. 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 309.28, 311.xx Anxiety 293.84, 300.0x, 300.2x, 300.3x, 309.24, 308.0x, 309.81 Sleep disorder 307.4x, 327.0x, 327.2x 780.5x, 347.xx Dementia (and related) 290.xx, 294.xx, 330.xx, 331 0312, 0313, 0314, 0316, 0317, 0318, 0319, 0326, 0327, 0329, 0330, 0331, 0332, 0333, 0334, 0335, 0336, 0337, 0338, 0339, 0340, 0341, 0342, 1046, 1113, 1127, 1133, 1419, 1423, 1643, 1646, 1661, 1673, 1694, 1697, 1719, 1721, 1726, 1743, 1755, 1764, 1785, 1790, 1791, 1832, 1854, 1860, 1864, 1865, 1903, 1927, 1940, 2050, 2068, 2073, 2189, 2208, 2219, 2228, 2233, 2249, 2254, 2280, 2286, 2313, 2314, 2324, 2340, 2354, 2359, 2373, 2375, 2378, 2384, 2392, 2403, 2446, 2485, 2574, 2607, 2610, 2613, 2614, 2615, 2628, 2644, 2677, 2736, 2790, 2811, 2826, 2835, 2837, 2842, 2889, 2904, 2930, 2978, 2996, 3122, 3150, 3241, 3268, 3350, 3531, 3564, 3765, 3777, 3812, 4135 240,204,825,845 The supplemental indications were classified into three mutually exclusive categories: 'new indication', 'modification' of an already approved indication, and 'expansion' in patient population. 1 New indication meant that no similar use was ever previously approved for the medication. An example of 'modification' is a diabetes drug being used to treat the same condition (e.g., diabetes mellitus) as its initial approval, but now it can be used in combination with another diabetes medication. Expansion generally referred to a drug being used to treat the same condition (e.g., diabetes mellitus) but in a different age group (e.g., children
with diabetes mellitus).
We identified 138 new indications, 86 modifications to the initial indication, and 66 expansions to the initial indication. We focused on new indications since these require a high level of evidence (i.e., randomized clinical trial) before they are granted.
Of the 138 new indications, 108 (78.3%) of the clinical trials supporting the new indications had a primary outcome that was not identifiable in US longitudinal healthcare databases (e.g., pathology results, change in clinical scores, radiologic tumour response), 12 (8.70%) of the trials did not have an active comparator (i.e., placebo-controlled trials), 4 (2.90%) of the trials were based predominantly on in-hospital medication administration (e.g., postoperative nausea medication, anesthetic medications), and 14 (10.14%) of trials were potentially replicable.
Of the 14 potentially replicable trials we selected telmisartan and did not run analyses on the other 13. Of the remaining 13, most (N=8) were related to low molecular weight heparin A M A A medications or direct oral acting anticoagulants where the initial indication was typically venous thromboembolism prophylaxis, for example, and the new indication was the treatment of venous thromboembolism. Of the remaining five, two had laboratory based outcomes (e.g., change in cholesterol or blood glucose) which are not currently identifiable in most US longitudinal healthcare claims databases, one was an anti-rejection medication (i.e., tacrolimus) to prevent graft rejection following heart transplant, one was a medication (i.e., candesartan) for the treatment of heart failure, and one was an anticoagulant (i.e., bivalirudin) used for patients undergoing percutaneous coronary intervention.
